Trials / Completed
CompletedNCT03593200
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | Complement (C3) Inhibitor |
Timeline
- Start date
- 2018-08-16
- Primary completion
- 2019-10-22
- Completion
- 2019-10-22
- First posted
- 2018-07-20
- Last updated
- 2020-12-22
- Results posted
- 2020-12-22
Locations
3 sites across 2 countries: Bulgaria, Serbia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03593200. Inclusion in this directory is not an endorsement.